Pharmacokinetics, dose adjustments, and 6‐mercaptopurine/ methotrexate drug interactions in two patients with thiopurine methyltransferase deficiency
- 2 January 1998
- journal article
- Published by Wiley in Acta Paediatrica
- Vol. 87 (1), 108-111
- https://doi.org/10.1111/j.1651-2227.1998.tb01399.x
Abstract
No abstract availableKeywords
This publication has 13 references indexed in Scilit:
- Thiopurine Methyltransferase Pharmacogenetics: Human Gene Cloning and Characterization of a Common PolymorphismDNA and Cell Biology, 1996
- Risk of relapse in childhood acute lymphoblastic leukemia is related to RBC methotrexate and mercaptopurine metabolites during maintenance chemotherapy. Nordic Society for Pediatric Hematology and Oncology.Journal of Clinical Oncology, 1995
- Mercaptopurine metabolism and risk of relapse in childhood lymphoblastic leukaemiaThe Lancet, 1994
- Congenital thiopurine methyltransferase deficiency and 6-mercaptopurine toxicity during treatment for acute lymphoblastic leukaemia.Archives of Disease in Childhood, 1993
- Azathioprine-induced myelosuppression in thiopurine methyltransferase deficient heart transplant recipientThe Lancet, 1993
- Studies Strategies and DesignJournal of Pediatric Hematology/Oncology, 1993
- Methylation pharmacogenetics: Thiopurine methyltransferase as a model systemXenobiotica, 1992
- Altered mercaptopurine metabolism, toxic effects, and dosage requirement in a thiopurine methyltransferase-deficient child with acute lymphocytic leukemiaThe Journal of Pediatrics, 1991
- Analysis of 6-mercaptopurine, 6-thioguanine nucleotides, and 6-thiourie acid in biological fluids by high-performance liquid chromatography: Technical NoteScandinavian Journal of Clinical and Laboratory Investigation, 1989
- Variable Bioavailability of Oral MercaptopurineNew England Journal of Medicine, 1983